Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Astria Therapeutics, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit. The focus on this technology area reflects the company's current patenting priorities and its technical expertise in this sector.
The busiest examiner, CHEONG, CHEOM-GIL, is responsible for 1 pending office action. This single action represents the total of 1 pending office action for the company. The prosecution is currently limited to a single examiner and a single art unit, providing a streamlined administrative path for the applicant.
Because there is only 1 distinct examiner involved, the company's strategy for its 1 pending office action is centered on the review by CHEONG, CHEOM-GIL. The presence of 1 distinct art unit indicates a specific regulatory environment within the Biotechnology & Pharmaceuticals field. This concentrated approach allows the company to focus its efforts on a single point of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615934 | ANTI-PLASMA KALLIKREIN ANTIBODY DOSING REGIMENS FOR TREATING HEREDITARY ANGIOEDEMA | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18615934 | ANTI-PLASMA KALLIKREIN ANTIBODY DOSING REGIMENS FOR TREATING HEREDITARY ANGIOEDEMA | CHEONG, CHEOM-GIL | 1645 | DP | Final Rejection | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstria Therapeutics, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Cheom-Gil Cheong has the most, with 1 of Astria Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
